Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of TU2218, an Oral TGFβR Serine/Threonine Kinase Inhibitor, Administered in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

NCT05784688 is registered in ClinicalTrials.gov with TiumBio Co., Ltd. as lead sponsor.

NCT NCT05784688
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05784688 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of TU2218, an Oral TGFβR Serine/Threonine Kinase Inhibitor, Administered in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Lead sponsor
TiumBio Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 10, 2023
Completion date
December 31, 2028
Enrollment
140 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer, colorectal cancer, head and neck squamous cell carcinoma, solid tumor